Share of the population living with HIV receiving antiretroviral therapy in Mozambique

Mozambique: Share of the population living with HIV receiving antiretroviral therapy was 81.9% in 2024. ◆ Volatile

Latest (2024)
81.9%
Change on year
up 6.0%
World rank
48th
of 149 countries
All-time high
81.9%
in 2024
All-time low
0.0%
in 1990
Years of data
35
1990–2024

Share of the population living with HIV receiving antiretroviral therapy in Mozambique, 1990–2024

0204060801990200720241990: 0 %1991: 0 %1992: 0 %1993: 0 %1994: 0 %1995: 0 %1996: 0 %1997: 0 %1998: 0 %1999: 0 %2000: 0 %2001: 0 %2002: 0 %2003: 0.292 %2004: 0.621 %2005: 1.5 %2006: 3.3 %2007: 6.8 %2008: 9.5 %2009: 11.2 %2010: 13.8 %2011: 16.4 %2012: 17.7 %2013: 26 %2014: 34.2 %2015: 40.7 %2016: 48.4 %2017: 54.6 %2018: 55.5 %2019: 59.5 %2020: 61.2 %2021: 66.8 %2022: 72.4 %2023: 77.3 %2024: 81.9 %

Source: Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data. Measured in %.

Analysis

The most recent figure for share of the population living with hiv receiving antiretroviral therapy in Mozambique is 81.9%, measured in 2024. That is the highest value across all 35 years on record.

The figure is up 6.0% on the previous year and up 139.7% over ten years.

Over the whole period, share of the population living with hiv receiving antiretroviral therapy in Mozambique peaked at 81.9% in 2024 and was at its lowest, 0.0%, in 1990.

That places Mozambique 48th out of 149 countries with data for 2024, putting it in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Share of the population living with HIV receiving antiretroviral therapy in Mozambique, year by year

Annual values for Share of the population living with HIV receiving antiretroviral therapy in Mozambique, 1990 to 2024.
Year % Change
1990 0.0% —
1991 0.0% —
1992 0.0% —
1993 0.0% —
1994 0.0% —
1995 0.0% —
1996 0.0% —
1997 0.0% —
1998 0.0% —
1999 0.0% —
2000 0.0% —
2001 0.0% —
2002 0.0% —
2003 0.3% —
2004 0.6% +112.6%
2005 1.5% +141.8%
2006 3.3% +121.9%
2007 6.8% +105.0%
2008 9.5% +39.2%
2009 11.2% +18.1%
2010 13.8% +22.6%
2011 16.4% +19.2%
2012 17.7% +8.1%
2013 26.0% +46.6%
2014 34.2% +31.4%
2015 40.7% +19.3%
2016 48.4% +18.7%
2017 54.6% +12.9%
2018 55.5% +1.7%
2019 59.5% +7.2%
2020 61.2% +2.8%
2021 66.8% +9.1%
2022 72.4% +8.4%
2023 77.3% +6.8%
2024 81.9% +6.0%

Mozambique compared with similar countries

  • Mozambique's 81.9% is above the median for low income countries, which is 69.8%, 1.2× the median. (24 countries reporting)
  • Mozambique's 81.9% is above the median for Sub-Saharan Africa, which is 81.2%, 1.0× the median. (44 countries reporting)

Biggest year-on-year movements

Years where Share of the population living with HIV receiving antiretroviral therapy in Mozambique changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.

YearChange FromTo
2005 +141.8% 0.6% 1.5%

Averages by decade

DecadeAverage LowestHighest Years
1990s 0.0% 0.0% 0.0% 10
2000s 3.3% 0.0% 11.2% 10
2010s 36.7% 13.8% 59.5% 10
2020s 71.9% 61.2% 81.9% 5

Countries ranked near Mozambique

  1. 45 Ecuador 82.1% compare
  2. 46 Burkina Faso 82.0% compare
  3. 47 Portugal 82.0% compare
  4. 49 Tajikistan 81.2% compare
  5. 50 South Africa 80.6% compare
  6. 51 Cape Verde 80.3% compare

See the full ranking of 149 places →

More reference data data for Mozambique

All data for Mozambique →

Frequently asked questions

What is share of the population living with hiv receiving antiretroviral therapy in Mozambique?
Share of the population living with hiv receiving antiretroviral therapy in Mozambique was 81.9% in 2024, according to Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data.
What is the highest share of the population living with hiv receiving antiretroviral therapy recorded in Mozambique?
The highest recorded value was 81.9% in 2024.
What is the lowest share of the population living with hiv receiving antiretroviral therapy recorded in Mozambique?
The lowest recorded value was 0.0% in 1990.
How does Mozambique rank for share of the population living with hiv receiving antiretroviral therapy?
Mozambique ranks 48th out of 149 countries with data for 2024.
Is share of the population living with hiv receiving antiretroviral therapy rising or falling in Mozambique?
Over the last ten years it is up 139.7%. The long-run trend across the full record is volatile.
Where does this Mozambique data come from?
The figures come from Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as part of Share of the population living with HIV receiving antiretroviral therapy. Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 35 observations, free to reuse under CC BY 4.0 (Our World in Data).

Share, cite or embed this page

Cite this page

Share of the population living with HIV receiving antiretroviral therapy in Mozambique. Statizoid, drawing on Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data. Retrieved 29 September 2026, from https://reference.statizoid.com/stat/gap-to-reaching-the-target-of-art/mozambique/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (Our World in Data); please keep the attribution.

<a href="https://reference.statizoid.com/stat/gap-to-reaching-the-target-of-art/mozambique/">Share of the population living with HIV receiving antiretroviral therapy in Mozambique</a> — Statizoid

About this data

Indicator
Share of the population living with HIV receiving antiretroviral therapy
Unit
%
Source
Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
149 places, 5,062 data points, 1990–2024
Last refreshed

Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.